Uninteresting Conflicts of Interest  by Shuster, Sam
Uninteresting Conflicts of Interest
Journal of Investigative Dermatology (2007) 127, 2668; doi:10.1038/sj.jid.5701108; published online 4 October 2007
TO THE EDITOR
As a biomedical researcher, albeit in a
long-gone, pre-geriatric existence, I
was more saddened than involved by
the Stossel/Williams spat (Stossel, 2007;
Williams, 2007), because theirs isn’t a
conflict: the boys are having a phoney
war with wooden swords and paper
hats. But it is now past bedtime, the toys
can be put away and grandpa will have
to tidy up.
Of course lots of people get fame
and fortune from papers, lectures and
opinion-leadering; and of course this
influences what they do and say (pace
Stossel); and of course public self-
exposure will make no difference (pace
Williams). But you can forget the
wooden swords and paper hats, be-
cause, absurd though it may be, the
intellectual flashing of ‘COI’ now has to
be tolerated––just as my generation had
to tolerate the inquisitorial baring of
souls to ethical committees, despite
their irrelevance to, and inhibition of,
research (Shuster, 1979). Medical his-
tory will record the titillating scandal of
an ethical committee spawning a bas-
tard offspring, the COI.
So my response to the pro- and anti-
COI flashers is a curse on both your
palaces. The real problem is the almost
complete absence of real biomedical
research; and, sadly, most people be-
lieve the recyclable rubbish now pro-
duced (the inane trials and correlative
epidemiology done outside the labs,
and the pointless technology, such as
gene fishing, done within them) is the
real thing.
This ‘conflict’ is as irrelevant as Aunt
Sally’s dead husband: all that matters is
the quality of research, and I don’t give
a toss whether Watson and Crick were
being secretly supported by God, the
Devil or both.
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TO THE EDITOR
We write to respond to points raised by
Dr Rees in the recent editorial ‘‘The
Nature of Clinical Evidence: Floating
Currencies Rather than Gold Stan-
dards’’ (Rees, 2007).
We agree with Dr Rees that change
is the only constant (Heraclites, c. 475
BC) in clinical evidence, that clinical
decisions should be based on the best
available evidence (Collier et al.,
2006), and that randomized controlled
trials (RCTs) are not always necessary
(Glasziou et al., 2007). Furthermore,
the results of single RCTs, even when
published in highly prestigious journals,
can be hazardous when read in isola-
tion (Ioannides, 2005), highlighting the
need for systematic reviews of all
available RCTs. Rees points out that
RCTs should not be blindly regarded as
a ‘‘fixed’’ gold standard. We agree.
While RCTs offer the strongest design to
minimize bias in human intervention
studies, their quality (in terms of design,
conduct, analysis, reporting, and rele-
vance) is highly variable, furthering
the argument for systematic reviews
to draw attention to such multidi-
mensional components (Bigby, 2003;
Williams, 2003).
Because systematic reviews are
the most cited form of clinical litera-
ture (Patsopoulos et al., 2005), if one
accepts citation impact as a measure of
importance, we disagree that the im-
portance of systematic reviews has
‘‘never been subject to experimental
study’’ (Rees, 2007). Systematic reviews
of all available evidence are also the
main source of evidence used by the UK
National Institute of Health and Clinical
Excellence (http://www.nice.org.uk/)
and the US Agency for Healthcare
Research and Quality (http://www.
ahrq.gov/) to inform health policy.
We agree with Rees that there is
increasing awareness that ‘‘failure to
report studies may lead to error’’ (Rees,
2007). For example, the concealment of
serious cardiovascular adverse events
for rofecoxib made a significant differ-
ence to the positive light thrown on the
drug from other trials at that time
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